4SC AG — Board/Management Information 2013

Mar 6, 2013

News Details

Ad-hoc | 6 March 2013 09:53

4SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner

4SC AG / Key word(s): Change of Personnel

06.03.2013 09:53

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Ad hoc announcement in accordance with §15 WpHG (German Securities Trading
Act)

4SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management
Board on 31 March 2013; his successor will be CFO Enno Spillner

Planegg-Martinsried, 6 March 2013 - 4SC AG (Frankfurt, Prime Standard:
VSC), a discovery and development company of targeted small molecule drugs
for autoimmune diseases and cancer, today announced that its Chief
Executive Officer (CEO) and Chairman of the Management Board, Dr Ulrich
Dauer, will be stepping down effective 31 March 2013 for personal reasons.

Dr Dauer, a founding member of 4SC and CEO of 4SC AG since 2000, is leaving
the company by mutual agreement with the Supervisory Board and in a spirit
of solidarity with the Management Board and will remain on amicable terms
with the company.

The Supervisory Board of 4SC AG would like to thank Dr Dauer for his
successful work over many years and his outstanding commitment to the
company.

Enno Spillner, the company's CFO since 2005, has been appointed by the
Supervisory Board as the CEO of 4SC AG with effect from 1 April 2013 and
will hold both positions, CFO and CEO, in the future.

---

Information and Explaination of the Issuer to this News:

Dr Thomas Werner, Chairman of the Supervisory Board of 4SC AG, said: 'Dr
Dauer has made a great contribution to building up the company's reputation
and establishing 4SC as one of Germany's most innovative biotechnology
companies. We are sorry to lose him and would like to thank him for his
successful work over many years and his outstanding commitment to the
company. I wish him all the best for the future. Dr Dauer's departure on 31
March and the transfer of his position to Mr Spillner effective 1 April
shall allow for an orderly handover as well as stable continuation of
business within 4SC's Management Board.'

Enno Spillner, CFO and designated CEO and Chairman of the Management Board
of 4SC AG, said: 'In the course of over 14 years at 4SC, Ulrich Dauer was
instrumental in shaping the company into what it is today. On behalf of the
Management Board of 4SC AG and the entire company, I would like to thank
him for his great contributions to the company and for his dedicated and
constructive collaboration as a friend of our company.'

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various autoimmune and cancer indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's balanced pipeline comprises promising products that are
in various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical companies. Founded in 1997, 4SC had 86 employees at
the end of 2012. 4SC AG has been listed on the Prime Standard of the
Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

For more information please visit www.4sc.com or contact:

4SC AG
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-63-66

MC Services
Mareike Mohr, Raimund Gabriel
mareike.mohr(at)mc-services.eu , Tel.: +49-89-2102-28-40
raimund.gabriel(at)mc-services.eu , Tel.: +49-89-2102-28-30

The Trout Group
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1-646-378-2947

06.03.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---